Dr. Leslie Thomas Busby, MD

Dr. Busby practices at Rocky Mountain Cancer Centers in Boulder, Colorado.

Dr. Busby's NPI, 1952385502, was assigned on December 6, 2005. Dr. Busby graduated from UNR Med in 1996. Dr. Busby holds Colorado license 40330.

Dr. Busby's primary practice is Rocky Mountain Cancer Centers, at 4715 Arapahoe Ave, Boulder, CO 80303 in Boulder County. The practice phone is (303) 930-7800.

Dr. Busby's primary practice is Rocky Mountain Cancer Centers in Boulder, Colorado. Dr. Busby is also affiliated with Foothills Hospital. The medical group on file is Rocky Mountain Cancer Centers. Dmand AI also links Dr. Busby to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Busby practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Busby's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Busby is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Busby's licenses on file in 2 states: Colorado and Utah.

Dmand AI lists breast cancer, chronic anemia, chronic leukemia, colorectal cancer, immune deficiency disease, lung cancer, lymphoma and multiple myeloma among the conditions Dr. Busby treats.

CMS data shows 40,946 Medicare services from Dr. Busby across 43 procedure codes in 2024, for 471 Medicare patients. Medicare paid $1,202,902 for them.

CMS counts 471 Medicare patients who saw Dr. Busby in 2024. The largest group is 65 to 74, with 208 patients. 60% of them have high cholesterol, and 55% have high blood pressure. 8% are also on Medicaid. Their average risk score is 1.92, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Busby's median patient age at 74, with 51% women.

In 2024, Dr. Busby wrote 1,181 Medicare Part D claims for 161 patients. 68% of them were for generic drugs. CMS names the drug for 927 of them, across 33 drugs with 11 or more claims each, at $3,240,530 in total drug cost. In 2023, CMS named 689 claims across 27 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 73 out of 100 for Dr. Busby for performance year 2024, reported through an alternative payment model (APM). Dr. Busby accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 4 papers to Dr. Busby in 2015. 2015 was the busiest year, with 2. The most frequent topics are Stroke, Time-to-Treatment and Tissue Plasminogen Activator. Dr. Busby has published most often in J Neurointerv Surg. Dr. Busby's most frequent co-authors are Samish Dhungana, MD, Ahmad Khaldi, MD and Kumiko Owada, MD.

CMS Open Payments shows 53 general payments to Dr. Busby from 21 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 70% of the total. AstraZeneca Pharmaceuticals LP paid the most, $11,512.

Dmand AI lists 1 award for Dr. Busby, most recently CMS Stage 1 2012 in 2012.

Dr. Busby graduated from UNR Med in 1996. Dr. Busby is a member of ACP and ASCO.

Dr. Busby is in network with 17 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.